Your browser doesn't support javascript.
loading
Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
Delpont, Benoit; Lhommée, Eugénie; Klinger, Hélène; Schmitt, Emmanuelle; Bichon, Amélie; Fraix, Valérie; Castrioto, Anna; Quesada, Jean-Louis; Pélissier, Pierre; Kistner, Andrea; Carnicella, Sébastien; Lüscher, Christian; Broussolle, Emmanuel; Pollak, Pierre; Thobois, Stéphane; Krack, Paul.
Afiliação
  • Delpont B; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
  • Lhommée E; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
  • Klinger H; Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
  • Schmitt E; Service de Neurologie C, Université Lyon I, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Lyon, France.
  • Bichon A; CNRS, UMR 5229, Centre de Neurosciences Cognitives, Lyon, France.
  • Fraix V; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
  • Castrioto A; Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
  • Quesada JL; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
  • Pélissier P; Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
  • Kistner A; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
  • Carnicella S; Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
  • Lüscher C; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
  • Broussolle E; Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
  • Pollak P; Unité Scientifique de la DRCI et Centre d'Investigation Clinique, CHU de Grenoble, Grenoble, France.
  • Thobois S; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
  • Krack P; Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Université Grenoble Alpes, Grenoble, France.
Mov Disord ; 32(11): 1566-1573, 2017 Nov.
Article em En | MEDLINE | ID: mdl-28737225
ABSTRACT

BACKGROUND:

Dopamine replacement therapy in PD has been associated with both behavioral addictions and dopamine addiction.

OBJECTIVES:

To investigate potential association between l-dopa induced neuropsychiatric fluctuations and addictions in PD.

METHODS:

A cohort of 102 patients with PD suffering from motor complications of l-dopa treatment was prospectively analyzed. We evaluated dopamine addiction, behavioral addictions, and neuropsychiatric fluctuations using the Ardouin scale of behavior in PD.

RESULTS:

Patients with (n = 51) or without (n = 51) neuropsychiatric fluctuations did not differ in age, disease duration, medication, or UPDRS III motor score during on and off drug condition. Patients with neuropsychiatric fluctuations had a higher H & Y stage in off-drug condition. A multivariate model showed that dopamine addiction (odds ratio 8.9; P = 0.02) and behavioral addictions (odds ratio 3.76; P = 0.033) were more frequent in the presence of neuropsychiatric fluctuations. Behavioral addictions and dopamine addiction were more frequent in the presence than in the absence of on-drug euphoria (46% vs. 13.9%; P < 0.001 and 27% vs 6.2 %; P = 0.003), while conversely, no association emerged between dopamine or behavioral addictions and presence of off-drug dysphoria. Patients with neuropsychiatric fluctuations had a poorer quality of life and a more frequent history of anxiety disorder.

CONCLUSIONS:

The psychostimulant effects of dopamine treatment during on-drug euphoria, rather than avoidance of off-drug dysphoria, appear to drive both behavioral addictions and abuse of medication. © 2017 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Dopaminérgicos / Levodopa / Comportamento Aditivo / Transtornos Relacionados ao Uso de Substâncias / Transtorno Depressivo / Euforia / Estimulantes do Sistema Nervoso Central Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Dopaminérgicos / Levodopa / Comportamento Aditivo / Transtornos Relacionados ao Uso de Substâncias / Transtorno Depressivo / Euforia / Estimulantes do Sistema Nervoso Central Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article